RxDoctor Payments Data

Jose Simon Canellas, MD

Neurology · Miami, FLNPI 1730370768

Payments from drug & device makers

$2,104in general payments, 2019–2025

Across 98 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$416
  • Neurocrine Biosciences, Inc.$378
  • AbbVie$217
  • Johnson & Johnson$202
  • Novartis$194
  • Argenx US, Inc.$122
  • plus $576 from 15 others

What the payments were for

  • Food & beverage$1,78685%
  • Education$31915%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,104 in reported general payments places this provider in the 45th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$84,452
Medicare patients
145
Services billed
459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4627$331,511
Gamunex-CImmune Globul G/Gly/Iga Avg 4618$218,149
Ajovy AutoinjectorFremanezumab-Vfrm85$76,562
RytaryCarbidopa/Levodopa192$65,803
Galantamine Hbr1,077$51,826
BotoxOnabotulinumtoxina43$50,696
Rasagiline Mesylate142$37,659
Nurtec OdtRimegepant Sulfate25$36,198
QuliptaAtogepant31$33,088
Memantine Hcl ErMemantine Hcl191$30,775
UbrelvyUbrogepant23$24,541
NamzaricMemantine Hcl/Donepezil Hcl27$19,619
Aimovig AutoinjectorErenumab-Aooe20$14,609
Emgality PenGalcanezumab-Gnlm21$14,320
VimpatLacosamide11$12,393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Qulipta, Ubrelvy, Namzaric$217$127,944124 claims
Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil, Pyridostigmine Bromide$84$71,584302 claims
UCB, Inc.Vimpat$47$12,39311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,434 neurology providers in Florida.

Other neurology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →